Pancragen vs Tirzepatide
A side-by-side research comparison of Pancragen and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pancragen | Tirzepatide |
|---|---|---|
| Full name | Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (peptide bioregulator) | FDA Approved |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | ~575 Da | 4,814 Da |
| Half-life | Short (peptide) | 5 days (120 hours) |
| Bioavailability | Oral (encapsulated) or subcutaneous | High (SubQ ~80%) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 2.5 mg → titrate up to 15 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Pancragen reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.